BioNTech SE (BNTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
Is BioNTech SE stock overvalued or undervalued in 2026?
As of October 28, 2026, BioNTech SE (BNTX) trades at $87.99 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: BioNTech SE
Market cap $22B · 52 weeks $84 – $119 (26 % below the high) · P/E no earnings · Dividend none · Next earnings November 3, 2026 · expected EPS $0.84 · Closing price, Oct 28 · accounts published Aug 4.
- Valuation: P/Sales 8.2× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 6 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 9.5 %, borderline.
- Market cap / Cash 1.4×, borderline.
- Annual cash burn $1.81, passes.
- Total Debt 0.0×, passes.
Against its peers (reference peers) — BioNTech SE: P/E —; EV/EBITDA —; ROIC -9.2 %; $22.1B. Incyte Corporation (P/E 14.9×; EV/EBITDA 9.6×; ROIC 24.6 %; $23.7B), Genmab A/S (P/E 45.1×; EV/EBITDA 22.4×; ROIC 9.9 %; $35.2B), TG Therapeutics, Inc. (P/E 20.9×; EV/EBITDA 67.5×; ROIC 9.9 %; $8.8B).
Investor methods verdict
Would Buffett approve BioNTech today?
The Buffett Method would not approve BioNTech today: it fails its quality rules. Business quality: 36 out of 100 (price not included). Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Would Peter Lynch approve BioNTech today?
The Lynch Method approves BioNTech today. Business quality: 100 out of 100 (price not included). Lynch classifies it as a turnaround. Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Profitability
| Return on Equity | -9.16% |
| Return on Invested Capital | -9.25% |
| Return on Assets | -8.34% |
| Gross Margin | 68.95% |
| Operating Margin | -64.63% |
| Net Margin | -64.25% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 7.85 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 6.19 |
Price Performance
| 1 month | -10.73% |
| 3 months | -2.86% |
| Year-to-date | -7.57% |
| 1 year | -14.86% |
| 3 years | -5.64% |
| 5 years | -68.43% |
Dividend History
| Date | Amount |
|---|---|
| 2022-06-02 | $2.1110 |
Amounts adjusted for stock splits.
Related companies: INCY · GMAB · IBRX · TGTX · IOVA · XNCR
Explore sector: Healthcare · Biotechnology
More sections of BNTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks